

FORM PTO-1479 (Modified)

ATTY. DOCKET NO.  
24731-500G

SERIAL NO.  
09/824,906

MAY 17 2002  
LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
TRADEMARK STATEMENT

APPLICANT  
Gruenberg, M.

FILING DATE  
April 2, 2001

GROUP  
1644

TECH CENTER 1600/2900

MAY 23 2002

RECEIVED

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
M37	A	5	0	8	1	0	2	9	01/14/92	Zarling <i>et al.</i>	435	172.3	02/01/89
	B	5	8	1	4	2	9	5	09/29/98	Martin, Jr. <i>et al.</i>	424	1.29	07/13/94
	C	5	8	7	2	2	2	2	02/16/99	Chang	530	391.1	12/18/92
	D	6	1	2	9	9	1	6	10/10/00	Chang	424	179.1	11/25/92
	E	6	3	5	2	6	9	4	03/05/02	June <i>et al.</i>	424	93.71	03/10/95

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
M37	F	0	4	4	0	3	7	3	08/07/91	EP	—	—		
	G	9	2	0	0	0	9	2	01/09/92	PCT	—	—		
	H	9	4	1	2	1	9	6	06/09/94	PCT	—	—		

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

M37	I	Anderson <i>et al.</i> "Crosslinking CD3 with CD2 using Sepharose-immobilized antibodies enhances T lymphocyte proliferation," <i>Cell Immunology</i> <u>115</u> : 246-256 (1988).
	J	Anderson <i>et al.</i> "Cross-Linking of T3 (CD3) with T4 (CD4) enhances The proliferation of resting T lymphocytes" <i>The Journal of Immunology</i> <u>139</u> : 678-682 (1987).
	K	Baroja <i>et al.</i> "Cooperation Between an Anti-T Cell (Anti-CD28) Monoclonal Antibody and Monocyte-Produced IL-6 in the Induction of T Cell Responsiveness to IL-2," <i>The Journal of Immunology</i> <u>141</u> : 1502-7 (1988).
	L	Baroja <i>et al.</i> "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) provides a Helper Signal and Bypasses the Need for Accessory Cells in T-Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> <u>120</u> : 205-217 (1989).
	M	Borst <i>et al.</i> "The $\delta$ - and $\epsilon$ - chains of the human T3/T-cell receptor complex are distinct polypeptides," <i>Nature</i> <u>312</u> : 455-458 (1986).
	N	Ceuppens, J.L. and M.L. Baroja, "Monoclonal Antibodies to the CD5 Antigen Can Provide the Necessary Second Signal for Activation of Isolated Resting T Cells by Solid-Phase-Bound OKT3," <i>The Journal of Immunology</i> <u>137</u> : 1816-1821 (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSUREAPPLICANT  
Gruenberg, M.FILING DATE  
April 2, 2001GROUP  
1644

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PDs	O	Damle <i>et al.</i> "Differential Costimulatory Effects of Adhesion Molecules B7, ICAM-1, LFA-3, and VCAM-1 On Resting and Antigen-Primed CD4+ T Lymphocytes," <i>The Journal of Immunology</i> <u>148</u> : 1985-1992 (1992).
	P	Damle <i>et al.</i> "Stimulation Via the CD3 and CD28 Molecules Induces responsiveness To IL-4 in CD4+ CD29+ CD45R- Memory T Lymphocytes," <i>The Journal of Immunology</i> <u>143</u> : 1761-7 (1989)
	Q	Ding, L. <i>et al.</i> , "Activation of CD4+ T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation)," <i>European J. of Immunology</i> <u>24</u> : 859-866 (1994).
	R	Hawke <i>et al.</i> "Stimulation of human T cells by sparse antigen captured on immunomagnetic particles " <i>J. of Immunol. Methods</i> <u>155</u> : 41-48 (1992).
	S	Karawajew <i>et al.</i> "A simple and sensitive method to study effects mediated by soluble lymphokines as demonstrated by the interaction of CD4+ and CD8+ cell subsets during T cell activation," <i>The Journal of Immunological Methods</i> <u>173</u> : 27-31 (1994).
	T	Kuiper <i>et al.</i> "Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation," <i>European J. of Immunology</i> <u>24(9)</u> : 1956-60 (1994).
	U	Ledbetter <i>et al.</i> "Antibody Binding to CD5 (Tp67) and Tp44 Cell Surface Molecules: Effects on Cyclic Nucleotides, Cytoplasmic Free Calcium, and cAMP-Mediated Suppression," <i>The Journal of Immunology</i> <u>137(10)</u> : 3299-3305 (1986).
	V	Lum <i>et al.</i> "Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients," <i>Bone Marrow Transplantation</i> <u>12</u> : 565-571 (1993).
	W	Nijhuis <i>et al.</i> "Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies," <i>Cancer Immunol. Immunotherapy</i> <u>32</u> : 245-50 (1990).
	X	Pai <i>et al.</i> "Cross-linking CD28 leads to activation of 70-kDa S6 kinase," <i>European Journal of Immunology</i> <u>24(10)</u> : 2364-2368 (1994).
	Y	Scouten <i>et al.</i> "Reversible Immobilization of Antibodies on Magnetic Beads," <i>Analytical Biochem.</i> <u>205</u> : 313-318 (1992).
	Z	Urdahl <i>et al.</i> "Accessory Cell-derived Costimulatory Signals Regulate T Cell Proliferation," <i>Ann. N.Y. Acad. Sci.</i> <u>636</u> : 33-42 (1991).
	AA	Van Wauwe <i>et al.</i> "OKT3: A Monoclonal Anti-Human T Lymphocyte Antibody With Potent Mitogenic Properties," <i>The Journal of Immunology</i> <u>124(6)</u> : 2708-2713 (1980).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION & DISCLOSURE  
STATEMENTAPPLICANT  
Gruenberg, M.FILING DATE  
April 2, 2001GROUP  
1644

TECH CENTER 1600/2900

MAY 21 3 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


BB	Von Fliedner <i>et al.</i> "Production of Tumor Necrosis Factor- $\alpha$ by Naive Or Memory T Lymphocytes Activated via CD28," <i>Cellular Immunology</i> <u>139</u> : 198-207 (1992).
CC	Weber <i>et al.</i> "Activation Through CD3 Molecule Leads to Clonal Expansion of All Human Peripheral Blood T Lymphocytes: Functional Analysis of Clonally Expanded Cells, <i>The Journal of Immunology</i> <u>135</u> (4): 2337-2342 (1985).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644RECEIVED  
FEB 13 2001  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
MS	AA	3	8	2	1	0	8	7	6/28/74	Knazek <i>et al.</i>	195	127	5/18/72
	AB	3	8	8	3	3	9	3	5/13/75	Knazek <i>et al.</i>	195	1.8	2/11/74
	AC	3	9	9	7	3	9	6	12/14/76	Delente	195	1.8	7/02/73
	AD	4	0	8	7	3	2	7	5/02/78	Feder <i>et al.</i>	195	1.7	4/12/76
	AE	4	2	0	0	6	8	9	4/29/80	Knazek <i>et al.</i>	435	2	8/29/78
	AF	4	2	0	6	0	1	5	6/03/80	Knazek <i>et al.</i>	435	2	8/29/78
	AG	4	2	2	0	7	2	5	09/02/80	Knazek <i>et al.</i>	435	285	4/03/78
	AH	4	3	0	1	2	4	9	11/17/81	Markus <i>et al.</i>	435	235	7/23/80
	AI	4	3	9	1	9	1	2	7/5/83	Yoshida <i>et al.</i>	435	241	9/18/80
	AJ	4	5	4	6	0	8	3	10/08/85	Meyers <i>et al.</i>	435	240	4/22/83
	AK	4	6	2	9	6	8	6	12/16/86	Gruenberg	435	1	06/14/82
	AL	4	6	9	0	9	1	5	09/01/87	Rosenberg	514	2	08/08/85
	AM	4	7	2	2	9	0	2	02/02/88	Harm <i>et al.</i>	435	284	11/04/85
	AN	4	8	0	4	6	2	8	02/14/89	Cracauer <i>et al.</i>	435	240.242	08/19/87
	AO	4	8	0	8	1	5	1	02/28/89	Dunn, Jr. <i>et al.</i>	604	6	04/27/87
	AP	4	8	4	9	3	2	9	07/18/89	Leung <i>et al.</i>	435	2	04/20/87
	AQ	4	8	6	1	5	8	9	08/29/89	Ju	424	93	03/23/87
	AR	4	8	9	4	3	4	2	01/16/90	Guinn <i>et al.</i>	435	291	09/22/86
	AS	4	9	3	7	0	7	1	06/26/90	Cioco <i>et al.</i>	424	85.2	12/29/87
	AT	4	9	7	1	7	9	5	11/20/90	Longenecker <i>et al.</i>	424	93	07/21/88
	AU	4	9	7	3	5	5	8	11/27/90	Wilson <i>et al.</i>	435	240.242	04/28/88
	AV	4	9	9	9	2	9	8	03/12/91	Wolfe <i>et al.</i>	435	240.242	04/27/88
	AW	5	0	0	2	8	7	9	03/26/91	Bowlin <i>et al.</i>	435	71.1	12/05/89

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mail d:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906
 OFFICE OF PATENTS AND PUBLICATIONS FOR  
 APPLICANT'S INFORMATION DISCLOSURE  
 STATEMENT
APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
ms	AX	5	0	1	5	5	8	5	05/14/91	Robinson	435	240.242	02/23/88
	AY	5	0	4	1	2	8	9	08/20/91	Phillips <i>et al.</i>	424	85.2	11/13/87
	AZ	5	0	5	7	4	2	3	10/15/91	Hiserodt <i>et al.</i>	435	240.23	12/18/87
	BA	5	0	6	1	6	2	0	10/29/91	Tsukamoto <i>et al.</i>	435	7.21	03/30/90
	BB	5	0	6	4	7	6	4	11/12/91	Besnainon <i>et al.</i>	435	285	12/19/89
	BC	5	1	2	3	9	0	1	06/23/92	Carew	604	5	missing
	BD	5	1	2	6	1	3	2	06/30/92	Rosenberg	424	93	08/21/89
	BE	5	1	2	6	2	3	8	06/30/92	Gebhard <i>et al.</i>	435	3	02/15/90
	BF	5	1	4	7	2	8	9	09/15/92	Edelson	604	4	03/29/90
	BG	5	1	4	7	7	8	4	09/15/92	Peault	435	7.24	04/12/90
	BH	5	1	6	2	2	2	5	11/10/92	Sager <i>et al.</i>	435	240.243	07/15/91
	BI	5	1	8	8	9	6	9	02/23/93	Arai <i>et al.</i>	436	548	06/15/89
	BJ	5	1	9	2	5	3	7	03/09/93	Osband	424	85.2	08/19/91
	BK	5	2	0	2	2	5	4	04/13/93	Amiot <i>et al.</i>	435	240.242	10/11/90
	BL	5	2	2	9	1	1	5	07/20/93	Lynch	424	93	07/26/90
	BM	5	2	4	2	6	8	7	09/07/93	Tykocinski <i>et al.</i>	424	93	04/25/91
	BN	5	2	7	7	9	0	7	01/11/94	Loria	424	93	07/24/92
	BO	5	3	1	6	7	6	3	05/31/94	Ochoa <i>et al.</i>	424	85.2	07/10/92
	BP	5	3	2	6	7	6	3	07/05/94	Gluchowski <i>et al.</i>	514	249	01/29/93
	BQ	5	3	7	4	5	4	9	12/20/94	Leung	435	240.2	01/31/91
	BR	5	3	9	9	3	4	6	03/21/95	Anderson <i>et al.</i>	424	93.21	03/30/94
	BS	5	3	9	9	3	4	7	03/21/95	Trentham <i>et al.</i>	424	184.1	09/25/92
✓	BT	5	4	0	9	8	1	3	04/24/95	Schwartz	435	7.24	09/30/93

EXAMINER

DATE CONSIDERED


2/18/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
PS	BU	5	4	1	1	7	4	9	05/02/95	Mayo <i>et al.</i>	424	578	12/23/92
	BV	5	4	3	7	9	9	4	08/01/95	Emerson <i>et al.</i>	435	240.2	12/10/93
	BW	5	4	4	3	9	8	3	08/22/95	Ochoa <i>et al.</i>	435	240.2	03/21/88
	BX	5	4	5	9	0	6	9	10/17/95	Palsson <i>et al.</i>	435	289.1	01/06/94
	BY	5	4	6	6	5	7	2	11/14/95	Sasaki <i>et al.</i>	435	2	04/25/94
	BZ	5	4	7	0	7	3	0	11/28/95	Greenberg <i>et al.</i>	435	172.3	08/08/94
	CA	5	4	7	6	9	9	7	12/19/95	Kaneshima <i>et al.</i>	800	2	05/17/94
	CB	5	4	9	8	5	3	7	03/12/96	Bresler <i>et al.</i>	435	235.1	03/09/94
	CD	5	5	1	2	4	4	4	04/30/96	Patard <i>et al.</i>	435	6	11/30/94
	CE	5	5	9	9	7	0	5	02/04/97	Cameron	435	378	11/16/93
	CF	5	6	0	5	8	2	2	02/25/97	Emerson <i>et al.</i>	435	172.3	12/01/94
	CG	5	6	2	2	8	5	7	04/22/97	Goffe	435	378	08/08/95
	CH	5	6	2	7	0	7	0	05/06/97	Gruenberg	435	786.5	07/26/95
	CI	5	6	3	5	3	8	6	06/03/97	Palsson <i>et al.</i>	435	372	11/02/94
	CJ	5	6	3	5	3	8	7	06/03/97	Fei <i>et al.</i>	435	378	04/03/95
	CK	5	6	3	7	4	8	1	06/10/97	Ledbetter <i>et al.</i>	435	69.6	09/13/93
	CL	5	6	4	6	0	4	3	07/08/97	Emerson <i>et al.</i>	435	373	03/10/95
	CM	5	6	5	6	4	2	1	08/12/97	Gebhard <i>et al.</i>	435	3	02/12/91
	CM	5	6	7	6	8	4	9	10/14/97	Sammons <i>et al.</i>	210	806	03/08/95
	CO	5	7	1	8	8	8	3	02/17/98	Harlan <i>et al.</i>	424	9.2	02/17/94
	CP	5	7	2	8	5	8	1	03/17/98	Schwartz <i>et al.</i>	435	385	06/07/95
	CQ	5	7	6	3	2	6	1	06/09/98	Gruenberg	435	286.5	12/05/96
	CR	5	7	6	3	2	6	6	06/09/98	Palsson <i>et al.</i>	435	289.1	11/07/94

EXAMINER

DATE CONSIDERED

2/18/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
B3	CS	5	7	6	6	9	2	0	06/16/98	Babbit <i>et al.</i>	435	240.1	06/06/95
	CT	5	8	1	1	3	0	1	09/22/98	Cameron	435	372	08/07/96
	CU	5	8	5	8	3	5	8	01/12/99	June <i>et al.</i>	424	130.1	06/03/94
	CV	5	9	9	4	1	2	6	11/30/99	Steinman <i>et al.</i>	435	325	06/17/94

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
B3	CW	0	4	0	5	9	7	2	1/2/91	EPO	<del>A1</del>	—		
	CX	2	8	8	3	2	0	1	04/99	JP	<del>B2</del>	—	X	
	CY	9	0	0	5	5	4	1	05/31/90	PCT	—	—		
	CZ	9	0	1	5	8	7	7	12/27/90	PCT	—	—		
	DA	9	1	0	4	3	1	7	04/04/91	PCT	—	—		
	DB	9	1	1	8	9	7	2	12/12/91	PCT	—	—		
	DC	9	3	1	9	7	6	7	10/14/93	PCT	—	—		
	DD	9	4	2	2	4	8	9	10/13/94	PCT	—	—		
	DE	9	4	2	3	7	6	0	10/27/94	PCT	—	—		
	DF	9	4	2	8	9	1	2	12/22/94	PCT	—	—		
	DG	9	4	2	9	4	3	6	12/22/94	PCT	—	—		
	DH	9	5	2	9	6	7	3	11/09/95	PCT	—	—		
	DI	9	5	3	3	8	2	3	12/14/95	PCT	—	—		
	DJ	9	5	3	3	8	2	3	12/14/95	PCT	—	—		
	DK	9	6	3	4	9	5	6	11/07/96	PCT	—	—		

EXAMINER

DATE CONSIDERED

2/18/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
135	DL	9	6	3	4	9	7	0	11/7/96	PCT	-	-		
	DM	9	6	4	0	8	6	0	12/19/96	PCT	-	-		
	DN	9	6	4	0	8	7	6	12/19/96	PCT	-	-		
	DO	9	7	0	5	2	3	9	2/13/97	PCT	-	-		
	DP	9	7	3	1	6	4	7	09/04/97	PCT	-	-		
	DQ	9	8	2	5	4	5	7	06/18/98	PCT	-	-		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

135	DR	Alberts, B. <i>et al.</i> , " <u>Molecular Biology of the Cell</u> ", 3rd ed., Garland Publishing, Inc., <del>ppp</del> page 1169 (1994)
	DS	Autran <i>et al.</i> , A ThO/Th2-like function of CD4 <sup>+</sup> CD7 <sup>+</sup> T helper cells from normal donors and HIV-infected patients, <u>J. Immunol.</u> 154: 1408-1417 (1995)
	DT	Bartholeyns <i>et al.</i> , Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer, <u>Anticancer Research</u> 14: 2673-2676 (1994)
	DU	Benvenuto <i>et al.</i> , Enhanced production of interferon- $\gamma$ by T lymphocytes cloned from rejected kidney grafts, <u>Transplantation</u> 51: 887-890 (1991)
	DV	Benvenuto <i>et al.</i> , Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis, <u>Clin. Exp. Immunol.</u> 84: 97-102 (1991)
	DW	Bernhard <i>et al.</i> , Generation of immunostimulatory dendritic cells from human CD34 + hematopoietic progenitor cells of the bone marrow and peripheral blood, <u>Cancer Res.</u> 55: 1099-1104 (1995)
	DX	Boiardi <i>et al.</i> , Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients, <u>Cancer Immunol. Immunother.</u> 39: 193-197 (1994)
	DY	Brod <i>et al.</i> , Restricted T cell expression of IL-2/Ifn- $\gamma$ mRNA in human inflammatory disease, <u>J. Immunol.</u> 147: 810-815 (1991)

EXAMINER

DATE CONSIDERED

2/18/2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mail d:



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

131	DZ	Certified English language translation of the Japanese Patent No. 2883201
	EA	Cesano <i>et al.</i> , Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach, <i>J. Clin. Invest.</i> 94: 1076-1084 (1994)
	EB	Chen <i>et al.</i> , Donor T cells can be induced to grow and survive long term <i>in vivo</i> without previous host immunosuppression, <i>J. Immunol.</i> 152: 4767-4774 (1994)
	EC	Chen <i>et al.</i> , Regulatory T cell clone induced by oral tolerance: Suppression of autoimmune encephalomyelitis, <i>Science</i> 265: 1237-1240 (1994)
	ED	Cherwinski <i>et al.</i> , Two types of mouse helper T cell clone, <i>J. Exp. Med.</i> 166: 1229-1244 (1987)
	EE	Chick <i>et al.</i> , Beta cell culture on synthetic capillaries: An artificial endocrine pancreas, <i>Science</i> 187: 847-849 (1975)
	EF	Clerici <i>et al.</i> , A T <sub>H</sub> 1-T <sub>H</sub> 2 switch is a critical step in the etiology of HIV infection, <i>Immunology Today</i> 14.3: 107-111 (1993)
	EG	David <i>et al.</i> , Continuous production of carcinoembryonic antigen in hollow giber cell culture units: Brief communication, <i>J. Natl. Cancer Inst.</i> 60.2: 303-306 (Feb. 1978)
	EH	Davis, J.E. <i>et al.</i> , "Mass Transfer Between Capillary Blood and Tissues", <i>Chem. Eng. J.</i> , 7:213-225 (1974)
	EI	de Carli <i>et al.</i> , Cytolytic T cells with Th1- like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy, <i>J. Clin. Endocrinol. Metabol.</i> 77.5: 1120-1124 (1993)
	EJ	De Jong <i>et al.</i> , Maturation- and differentiation-dependent responsiveness of human CD4 <sup>+</sup> T helper subsets, <i>J. Immunol.</i> 149: 2795-2802 (Oct. 1992)
	EK	Del Prete <i>et al.</i> , High potential to tumor necrosis factor $\alpha$ (TNF- $\alpha$ ) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: A peculiar feature of destructive thyroid autoimmunity, <i>Autoimmunity</i> 4: 267-276 (1989)
	EL	Del Prete <i>et al.</i> , Purified Protein derivative of <i>Mycobacterium tuberculosis</i> and excretory-secretory antigen(s) of <i>Toxocara canis</i> expand <i>in vitro</i> human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production, <i>J. Clin. Invest.</i> 88: 346-350 (July 1991)

RECEIVED

OCT 15 2001

EXAMINER

DATE CONSIDERED

TECH CENTER 1600/2900 2/18/2007

EXAMINER: Initial if citation consid red, wh ther or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not consider d. Include c py of this form with n xt communication to applicant.

Titl : AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900



OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Patents already of record

EM	<del>Derwent #008306271 WPI Abs. No. 1990-193272/199025 (citing WO Patent Publication WO90/05541, the parent of Japanese Patent Publication No. JP 2883201, published April 19, 1999)</del>
EN	Dillman <i>et al.</i> , Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma, <u>Cancer</u> 68: 1-8 (1991)
EO	Dillman <i>et al.</i> , Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A national biotherapy study group trial, <u>J. Clin. Oncology</u> 9.7: 1233-1240 (1991)
EP	Eastcott <i>et al.</i> , Adoptive transfer of cloned T helper cells ameliorates periodontal disease in nude rats, <u>Oral Microbiol. Immunol.</u> 9: 284-289 (1994)
EQ	Elson <i>et al.</i> , T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for T <sub>H</sub> 2 cells, <u>Internat. Immunol.</u> 6: 1003-1009 (1993)
ER	Englemann <i>et al.</i> , Activation of human T lymphocyte subsets: Helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens, <u>J. Immunol.</u> 127: 2124-2129 (1981)
ES	Faradji <i>et al.</i> , Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients, <u>J. Immunol. Meth.</u> 174: 297-309 (1994)
ET	Fiorentino <i>et al.</i> , Two types of mouse T helper cell, <u>J. Exp. Med.</u> 170: 2081-2095 (1989)
EU	Firestein <i>et al.</i> , A new murine CD4 <sup>+</sup> T cell subset with an unrestricted cytokine profile, <u>J. Immunol.</u> 143: 518-525 (1989)
EV	Foon <i>et al.</i> , Renal cell carcinoma treated with continuous-infusion interleukin-2 with <i>ex vivo</i> -activated killer cells, <u>J. Immunotherapy</u> 11: 184-190 (1992)
EW	Foulis <i>et al.</i> , Insulinitis in type 1 (insulin-dependent) diabetes mellitus in Man-macrophages, lymphocytes, and interferon- $\mu$ containing cells, <u>J. Pathol.</u> 165: 97-103 (1991)
EX	Fowell <i>et al.</i> , Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 <sup>+</sup> T cell subset that inhibits this autoimmune potential, <u>J. Exp. Med.</u> 177: 627-636 (1993)
EY	Fowler <i>et al.</i> , Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice, <u>Advances in Bone Marrow Purging and Processing: Fourth International Symposium</u> , 533-540 (1994)

EXAMINER

DATE CONSIDERED

2/18/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

137	EZ	Freedman <i>et al.</i> , Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial, <u>J. Immunol.</u> 16: 198-210 (1994)
	FA	Galandrini <i>et al.</i> , Antibodies to CD44 trigger effector functions of human T cell clones, <u>J. Immunol.</u> 150: 4225-4235 (1993)
	FB	Gaudernack <i>et al.</i> , Isolation of pure functionally active CD8 <sup>+</sup> T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres, <u>J. Immun. Meth.</u> 90: 179-187 (1986)
	FC	Goedegbuure <i>et al.</i> , Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study, <u>J. Clin. Oncol.</u> 13: 1939-1949 (1995)
	FD	Gold <i>et al.</i> , Adoptive Tumor immunotherapy using human CD4 <sup>+</sup> T-cells, <u>Br. J. Cancer</u> 67: 865 (1993)
	FE	Gold <i>et al.</i> , Autolymphocyte therapy, <u>J. Surgical Res.</u> 59: 270-286 (1995)
	FF	Grabbe <i>et al.</i> , Dendritic cells as initiators of tumor immune responses: A Possible strategy for tumor immunotherapy, <u>Immunology Today</u> 16: 117-121 (1995)
	FG	Graham <i>et al.</i> , The use of <i>ex vivo</i> -activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study, <u>Seminars in Urology</u> 11: 27-34 (1993)
	FH	Grau <i>et al.</i> , Implications of cytokines in immunopathology: Experimental and clinical data, <u>Eur. Cytokine Net.</u> 1: 203-210 (1990)
	FI	Grimm <i>et al.</i> , Lymphokine-activated killer cell phenomenon, <u>J. Exp. Med.</u> 155: 1823-1841 (1982)
	FJ	Gullino <i>et al.</i> , Tissue culture on artificial capillaries, <u>Meth. Enzymol.</u> 58: 178-184 (1979)
	FK	Hager <i>et al.</i> , Tumor-associated antigens produced by mouse mammary tumor cells in artificial capillary culture, <u>J. Natl. Cancer Inst.</u> 69: 1359-1365 (1982)
	FL	Hammel <i>et al.</i> , Effect of interleukin-1 $\alpha$ on the <i>in vitro</i> activation of tumor-draining lymph node cells for adoptive immunotherapy, <u>J. Immunotherapy</u> 16: 1-12 (1993)
2	FM	Hansen <i>et al.</i> , Monoclonal antibodies identifying a novel T-cell antigen and Ia antigen of human lymphocytes, <u>Immunogenetics</u> 10: 247-260 (1980)

EXAMINER

DATE CONSIDERED

2/18/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

✓ 35	FN	Hara <i>et al.</i> , Human T cell activation, <u>J. Exp. Med.</u> 161: 1513-1524 (1985)
	FO	Henschler <i>et al.</i> , Maintenance of transplantation potential in <i>ex vivo</i> expanded CD34 <sup>+</sup> - selected human peripheral blood progenitor cells, <u>Blood</u> 84: 2898-2903 (1994)
	FP	Herberman <i>et al.</i> , Adoptive therapy with purified CD8 cells in HIV infection, <u>AIDS/Cancer Therapies</u> , 35-44.
	FQ	Ho <i>et al.</i> , A phase 1 study of adoptive transfer of autologous CD8 <sup>+</sup> lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS, <u>Blood</u> 81: 2093-2101 (1993)
	FR	Hsieh <i>et al.</i> , Differential regulation of T helper phenotype development by interleukins 4 and 10 in an $\alpha\beta$ T-cell-receptor transgenic system, <u>Proc. Natl. Acad. Sci. USA</u> 89: 6065-6089 (1992).
	FS	Huet <i>et al.</i> , T cell activation via CD2 [T, gp50]: The role of accessory cells in activating resting T cells via CD2, <u>J. Immunol.</u> 137: 1420-1428 (1986)
	FT	Igletseme <i>et al.</i> , Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, TH <sub>1</sub> Lymphocyte clone, <u>Regional Immunology</u> 5: 317-324 (1993)
	FU	Jensen <i>et al.</i> , Production of anchorage-dependent cells-problems and their possible solutions, <u>Biotechnol. Bioeng.</u> 23: 2703-2716 (1981)
	FV	June <i>et al.</i> , "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", <u>Molecular and Cell Biology</u> , Dec: 4472-4481 (1987)
	FW	Klimas <i>et al.</i> , Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion, <u>AIDS</u> 8: 1073-1081 (1994)
	FX	Knazek <i>et al.</i> , Cell culture on artificial capillaries: An approach to tissue growth <i>in vitro</i> , <u>Science</u> 173: 65-67 (1972)
	FY	Knazek <i>et al.</i> , Hormone production by cells grown <i>in vitro</i> on artificial capillaries, <u>Exp. Cell Res.</u> 84: 251-254 (1974)
✓	FZ	Knazek <i>et al.</i> , Brief communication: Formation of solid human mammary carcinoma <i>in vitro</i> , <u>J. Natl. Cancer Inst.</u> 58: 419-422 (1977)

EXAMINER

DATE CONSIDERED

2/18/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

 LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT
APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MS	GA	Koretz <i>et al.</i> , Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer, <u>Arch. Surg.</u> 126: 898-903 (1991)
	GB	Lane <i>et al.</i> , Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation, <u>Blood</u> 85: 275-282 (1995)
	GC	Lea <i>et al.</i> , Characterization of human mononuclear cells after positive selection with immunomagnetic particles, <u>Scand. J. Immunol.</u> 23: 509-519 (1986)
	GD	Lea <i>et al.</i> , Magnetic Monosized polymer particles for fast and specific fractionation of human mononuclear cells, <u>Scan. J. Immunol.</u> 22: 207-216 (1985)
	GE	Ledbetter <i>et al.</i> , Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells, <u>J. Immunol.</u> 135: 2331-2336 (1985)
	GF	Ledbetter <i>et al.</i> , Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression, <u>J. Immunol.</u> 135: 1819-1825 (1985)
	GG	Ledbetter <i>et al.</i> , Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor, <u>Eur. J. Immunol.</u> 18: 525-532 (1988)
	GH	Liblau <i>et al.</i> , Th1 and Th2 CD4 <sup>+</sup> T Cells in the pathogenesis of organ-specific autoimmune diseases, <u>Immunology Today</u> 16: 34-38 (1995)
	GI	Lindqvist <i>et al.</i> , Enhanced IL-4-mediated D10.G4.1 Proliferation with suboptimal concentrations of anti-IL-4 receptor Monoclonal antibodies, <u>J. Immunol.</u> 150: 394-398 (1993)
	GJ	Lum <i>et al.</i> , In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen, <u>Cell. Immunol.</u> 72: 122-129 (1982)
	GK	Luyten <i>et al.</i> , Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation, <u>J. Biol. Chem.</u> 264(23):13377-13380 (1989)
	GL	Lynch <i>et al.</i> , Interleukin 7 promotes long-term <i>in vitro</i> growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy <i>in vivo</i> , <u>J. Exp. Med.</u> 179: 31-42 (1994)
2	GM	Manetti <i>et al.</i> , CD30 expression by CD8 <sup>+</sup> T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 <sup>+</sup> CD30 <sup>+</sup> T cell clones in human immunodeficiency virus infection, <u>J. Exp. Med.</u> 180: 2407-2411 (1994)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Titl : AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ms	GN	Manger <i>et al.</i> , T cell activation: Differences in the signals required for IL 2 Production by nonactivated and activated T cells, <u>J. Immunol.</u> 135: 3669-3673 (1985)
	GO	Marcus <i>et al.</i> , The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced <i>in vivo</i> antitumor activity, <u>J. Immunotherapy</u> 15: 105-112 (1994)
	GP	Martin <i>et al.</i> , "A 44 Kilodalton Cell Surface Homodimer Regulates Interleukin 2 Production By Activated Human T Lymphocytes", <u>J. of Immunol.</u> 136(9): 3282-3287 (1986)
	GQ	Mastsumura <i>et al.</i> , Characteristics and <i>in vivo</i> homing of long-term T-cell Lines and clones derived from tumor-draining lymph nodes, <u>Cancer Res.</u> 54: 2744-2750 (1994)
	GR	Miller <i>et al.</i> , Large scale <i>ex vivo</i> expansion and activation of human natural killer cells for autologous therapy, <u>Bone Marrow Transplantation</u> 14: 555-562 (1994)
	GS	Mosmann <i>et al.</i> , TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties, <u>Ann. Rev. Immunology</u> 7: 145-173 (1989)
	GT	Mosmann <i>et al.</i> , The expanding universe of T-cell subset: Th1, Th2 and more, <u>Immunology Today</u> (March 1996).
	GU	Mosmann <i>et al.</i> , Two types of murine helper T cell clone, <u>J. Immunol.</u> 136: 2348-2357 (1986)
	GV	Mulder <i>et al.</i> , Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity, <u>Cancer Immunol. Immunother.</u> 41: 293-301 (1995)
	GW	Nabel <i>et al.</i> , An inducible transcription factor activates expression of human immunodeficiency virus in T cells, <u>Nature</u> , 326:711-3 (1987)
	GX	Nagler <i>et al.</i> , Red blood cell depletion and enrichment of CD34 <sup>+</sup> Hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD34 immunoselection, <u>Exp. Hematol.</u> 22: 1134-1140 (1994)
	GY	Nakajima <i>et al.</i> , Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression, <u>Proc. Natl. Acad. Sci. USA</u> 91: 7889-7893 (1994)
✓	GZ	Niessner <i>et al.</i> , Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR), <u>Clin. Exp. Immunol.</u> 101: 428-435 (1995)

EXAMINER

DATE CONSIDERED

2/18/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

RECEIVED

OCT 15 2001

TECH CENTER 160012900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HA	O'Garra <i>et al.</i> , Role of cytokines in determining T-lymphocyte function, <u>Immunology</u> 6: 458-466 (1994)
HB	Ohno <i>et al.</i> , Lectin-activated Killer cells rapidly induced by pokeweed mitogen conjugated beads and their <i>in vivo</i> antitumor effects, <u>Int. J. Immunopharmacol.</u> 16: 761-768 (1994)
HC	Okamoto <i>et al.</i> , The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells, <u>Cancer Immunol. Immunother</u> 40: 173-181 (1995)
HD	Okarma <i>et al.</i> , The AIS collector: A new technology for stem cell purification, <u>Advances in Bone Marrow Purging and Processing</u> 487-504 (1992)
HE	Oxholm <i>et al.</i> , Cytokine expression in labial salivary glands from patients with primary Sjogrens syndrome, <u>Autoimmunity</u> 12: 185-191 (1992)
HF	Palliard <i>et al.</i> , Simultaneous production of IL-2, IL-4, and IFN- $\gamma$ by activated human CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell clones, <u>J. Immunol.</u> 141: 849-855 (1988)
HG	Pierrès <i>et al.</i> , Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation, <u>Eur. J. Immunol.</u> 18: 685-690 (1988)
HH	<del>Polanski <i>et al.</i>, Differentiation of Th2 cells from precursors in peripheral blood, (submitted 1996)</del>
HI	Powrie <i>et al.</i> , Regulatory interactions between CD45RB <sup>High</sup> and CD45RB <sup>Low</sup> CD4 <sup>+</sup> T cells are important for the balance between protective and pathogenic cell-mediated immunity, <u>J. Exp. Med.</u> 179: 589-600 (1994)
HJ	Puchetti <i>et al.</i> , A T <sub>H</sub> 1-T <sub>H</sub> 2-like switch in candidiasis: New perspectives for therapy, <u>Trends Microbiol.</u> 3(6): 237-240 (1995)
HK	Quayle <i>et al.</i> , Theumatoid inflammatory T-cell clones express mostly Th-1 but also Th2 and mixed (Th0-like) cytokine patterns, <u>Scand. J. Immunol.</u> 38: 75-82 (1993)
HL	Reinherz <i>et al.</i> , Separation of functional subsets of human T cells by a monoclonal antibody, <u>Proc. Natl. Acad. Sci. USA</u> 76: 4061-4065 (1979)
HM	Riddell <i>et al.</i> , Principles for adoptive T cell therapy of human viral diseases, <u>Ann. Rev. Immunology</u> 13: 545-586 (1995)
HN	Riddell <i>et al.</i> , Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, <u>Science</u> 257: 238-241 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (M. dified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

 LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT
APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

135	HO	Riddell <i>et al.</i> , CD8 + cytotoxic T cell therapy of cytomegalovirus and HIV infection, <u>Immunology</u> 5: 484-491 (1993)
	HP	Romagnani <i>et al.</i> , Regulation of the development of type 2 T-helper cells in allergy, <u>Immunology</u> 6: 838-846 (1994)
	HQ	Romagnani <i>et al.</i> , HIV can induce a T <sub>H</sub> 1 to T <sub>H</sub> 0 shift, and preferentially replicates in CD4 <sup>+</sup> T-cell clones producing T <sub>H</sub> 2-type cytokines, <u>60th Forum in Immunology</u> , 611-617 (1994)
	HR	Romani <i>et al.</i> , Proliferating dendritic cell progenitors in human blood, <u>J. Exp. Med.</u> 180: 83-93, (1994).
	HS	Romani <i>et al.</i> , Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance, <u>Infection and Immunity</u> 59: 4647-4654 (1991)
	HT	Rosenberg <i>et al.</i> , Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, <u>N. Engl. J. Med.</u> 313: 1485-1492 (1985)
	HU	Rosenberg <i>et al.</i> , A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, <u>N. Engl. J. Med.</u> 316: 889-897 (1987)
	HV	Rosenberg <i>et al.</i> , Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, <u>N. Engl. J. Med.</u> 319: 1676-1680 (1988)
	HW	Rutzky <i>et al.</i> , Human colon adenocarcinoma cells. III. <i>In vitro</i> organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture, <u>J. Natl. Cancer Inst.</u> 63: 85-93 (1979)
	HX	Sacchi <i>et al.</i> , Induction of tumor regression in experimental model of human head and neck cancer by human A-Lak cells and IL-2, <u>Int. J. Cancer</u> , 47: 784-791 (1991)
	HY	Salgaller <i>et al.</i> , Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides, <u>Cancer Res.</u> 55: 4972-4979 (1995)
	HZ	Saoudi <i>et al.</i> , TH2 activated cells prevent experiential autoimmune unweoretinitis, a TH1-dependent autoimmune disease, <u>Eur. J. Immunol.</u> 23: 3096-3103 (1993)
✓	IA	Scott <i>et al.</i> , The role of T-cell subsets and cytokines in the regulation of infection, <u>Immunology Today</u> , 12: 346-348, (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Dat mailed:



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IB	Scott, P. <i>et al.</i> , "Role of Cytokines and CD4 + T-Cell Subsets in the Regulation of Parasite Immunity and Disease", <u>Immunol. Rev.</u> , 112:161-182 (1989)
IC	Seder <i>et al.</i> , Interleukin 12 acts directly on CD4 + T cells to enhance priming for interferon $\mu$ production and diminishes interleukin 4 inhibition of such priming, <u>Proc. Natl. Acad. Sci. USA</u> 90: 10188-10192 (1993)
ID	Sedlmayr <i>et al.</i> , Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells, <u>J. Immunotherapy</u> 10: 336-346 (1991)
IE	Shanafelt <i>et al.</i> , Costimulatory signals can selectively modulate cytokine production by subsets of CD4 <sup>+</sup> T cells, <u>J. Immunol.</u> 154: 1684-1690 (1995).
IF	Sher <i>et al.</i> , Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection, <u>Immunological Rev.</u> 127: 183-204 (1992).
IG	Shimizu <i>et al.</i> , Costimulation of proliferative responses of resting CD4 <sup>+</sup> T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin, <u>J. Immunol.</u> 145: 59-67 (1990)
IH	Simon <i>et al.</i> , Divergent T-cell cytokine patterns in inflammatory arthritis, <u>Proc. Natl. Acad. Sci. USA</u> 91: 8562-8566 (1994)
II	Spertini <i>et al.</i> , Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells, <u>J. Immunol.</u> 149: 65-70 (1992)
IJ	Springer <i>et al.</i> , Adhesion receptors of the immune system, <u>Nature</u> 346: 425-434 (1990)
IK	Sugie <i>et al.</i> , Stimulation of NK-like YT cells via leukocyte function-associated antigen (LFA)-1, <u>J. Immunol.</u> 154: 1691-1698 (1995)
IL	Swabb <i>et al.</i> , Diffusion and convection in normal and neoplastic tissues, <u>Cancer Res.</u> 34: 2814-2814 (1974)
IM	Sznol <i>et al.</i> , Adoptive immunotherapy, <u>Cancer Chemotherapy and Biological Responses Modifiers Annual</u> 14: 227-248 (1993)
IN	Takahashi <i>et al.</i> , Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion, <u>Jpn. J. Cancer Res.</u> 86: 861-866 (1995)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/P900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MS already ok record	IO	Tamura <i>et al.</i> , T cell activation through TCR/CD3 complex IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage, <u>J. Immunol.</u> 148: 2370-2377 (1992)
	<del>IP</del>	<del>Translation (not certified) of the Claims for the Japanese Patent No. 2883201</del>
	IQ	Tax <i>et al.</i> , Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells, <u>Nature</u> 304: 445-447 (1983)
	IR	Thompson <i>et al.</i> , Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma, <u>J. Clin. Oncol.</u> 10: 960-968 (1992)
	IS	Thygesen <i>et al.</i> , Immunity to experimental <i>Salmonella typhimurium</i> infections in rats, <u>APMIS</u> 102: 489-494 (1994)
	IT	Torpey, Effects of adoptive immunotherapy with autologous VS8+ T lymphocytes on immunologic parameters: Lymphocyte subsets and cytotoxic, <u>Clinical Immunol. Immunopathol.</u> 68: 263-272 (1993)
	IU	Toso, J.F. <i>et al.</i> , "MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-Specific Activation", <u>Cancer Res.</u> , 56:16-20 (1996)
	IV	Turner <i>et al.</i> , Human T cells from autoimmune and normal individuals can produce tumor necrosis factor, <u>Eur. J. Immunol.</u> 17: 1807-1814 (1987)
	IW	Tze <i>et al.</i> , Long-term survival of adult rat islets of Langerhans in artificial capillary culture units, <u>Diabetes</u> , 26: 185-191 (1977)
	IX	Urban <i>et al.</i> , The importance of Th2 cytokines in protective immunity to nematodes, <u>Immunological Reviews</u> , 127: 205-220 (1992)
	IY	Utsugi <i>et al.</i> , Prevention of recurrent diabetes in syngeneic islet-transplanted NOD Mice by transfusion of autoreactive T lymphocytes, <u>Transplantation</u> 57: 1799-1804 (1994)
	IZ	Van Lier <i>et al.</i> , Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen, <u>J. Immunol.</u> 139: 1589-1596 (1987)
	JA	Van Lunzen <i>et al.</i> , Investigations on autologous T-cells for adoptive immunotherapy of AIDS, <u>Cell Activation and Apoptosis in HIV Infection</u> , 6: 57-70 (1995)

EXAMINER

DATE CONSIDERED

2/18/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JB	Vandenberghe <i>et al.</i> , Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: Evidence for signal transduction through CD5, <u>Eur. J. Immunol.</u> 21: 251-259 (1991)
JC	Whiteside <i>et al.</i> , Generation and characterization of <i>ex vivo</i> propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus, <u>Blood</u> , 81: 2085-2092 (1993)
JD	Wolf <i>et al.</i> , Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries, <u>Tran. Amer. Soc. Artif. Int. Organs.</u> 21: 16-27 (1975)
JE	Yamamura <i>et al.</i> , Defining protective responses to pathogens: Cytokine profiles in leprosy lesions, <u>Science</u> 254: 277-279 (1991)
JF	Yang <i>et al.</i> , <i>In vitro</i> priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation, <u>J. Immunol.</u> 155: 3897-3903 (1995)
JG	Yannelli <i>et al.</i> , The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer, <u>Journal of Immunological Methods</u> 139: 1-16 (1991)
JH	Zhang <i>et al.</i> , T-cell cytokine responses in human infection with <i>Mycobacterium tuberculosis</i> , <u>Infectious Immunology</u> : 3231-3234 (1995)

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, M.FILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
A	5 1 2 3 9 0 1	06/23/92	Carew	604	5	
B	5 6 3 7 4 8 1	06/10/97	Ledbetter et al.	435	69.6	09/13/93
C	5 7 6 6 9 2 0	06/10/98	Babbitt et al.	435	240.1	06/06/95
D	5 8 5 8 3 5 8	01/12/99	June et al	424	130.1	06/03/94
E	5 9 9 4 1 2 0	11/30/99	Steinman et al.	435	325	06/17/94

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
F 2 8 8 3 2 0 1	04/99	JP B2			claims

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

G	<del>Certified English language translation of the Japanese Patent No. 2883201.</del>
H	<del>Derwent #008306271 WPI Acc. No. 1996-193272/199025 (citing, WO Patent Publication WO96/05541, the parent of Japanese Patent Publication No. JP 2883201, published April 19, 1999).</del>
I	<del>June et al., "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", Molecular and Cell Biology, Dec: 4472-4481 (1987).</del>
J	<del>Martin et al., "A 44 Kiledalton Cell Surface Homodimer Regulates Interleukin 2 Production By Activated Human T Lymphocytes", J. of Immunol. 136(9): 3282-3287 (1986).</del>
K	<del>Nabel et al., An inducible transcription factor activates expression of human immunodeficiency virus in T cells, Nature, 326:711-3, (1987).</del>
L	<del>Translation (not certified) of the Claims for the Japanese Patent No. 2883201.</del>

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.